Estrogen-induced uterine abnormalities in TIMP-1 deficient mice are associated with elevated plasmin activity and reduced expression of the novel uterine plasmin protease inhibitor serpinb7

Molecular Reproduction and Development

Volumn 76, Issue 2, 2009, Pages 160-172

  Zhang, Xuan ^a   Hoang, Etter ^a   Nothnick, Warren B ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN; PLASMIN; PLASMIN INHIBITOR; PROTEIN SERBINB7; PROTEIN SERPBINB2; PROTEIN SERPINB7; STEROID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM; ENZYME DEFICIENCY; EPITHELIUM CELL; FEMALE; MEDIATOR; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNINDEXED SEQUENCE; UTERUS CAVITY; UTERUS MALFORMATION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; DNA PRIMERS; ESTROGENS; FEMALE; IN SITU HYBRIDIZATION; MICE; MICROARRAY ANALYSIS; PLASMIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERPINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UROGENITAL ABNORMALITIES; UTERUS;

MUS;

EID: 59349083540     PISSN: 1040452X     EISSN: 10982795     Source Type: Journal    
DOI: 10.1002/mrd.20938     Document Type: Article

References (41)

1. Brenner RM, Rudolph L, Matrisian L, Slayden OD. 1996. Non-human primate models: Artificial menstrual cycles, endometrial matrix metalloproteinases and s.c. endometrial grafts. Hum Reprod 11:150-164.
2. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 1477:267-283.
3. Chirco R, Liu X-W, Jung K-K, Kim H-R. 2006. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25:99-113.
4. Cox KE, Sharpe-Timms KL, Kamiya N, Saraf M, Donnelly KM, Fazleabas AT. 2000. Differential regulation of stromelysin-1 (matrix metalloproteinase-3) and matrilysin (matrix metalloproteinase-7) in baboon endometrium. J Soc Gynecol Invest 7:242-248.
5. Dougherty KM, Pearson JM, Yang AY, Westrick RJ, Baker MS, Ginsburg D. 1999. The plasminogen activator inhibitor-2 gene is not required for normal murine development and survival. Proc Natl Acad Sci USA 96:686-691.
6. Feinberg RF, Kao LC, Haimowitz JE, Queenan JT, Jr., Wun TC, Strauss JF III, Kliman HJ. 1989. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunohistochemical marker of invading trophoblasts. Lab Invest 61:20-26.
7. Feng J, Woessner JF, Jr., Zhu C. 1998. Matrilysin activity in the rat uterus during the estrous cycle and implantation. J Reprod Fertil 114:347-350.
8. Feng Q, Liu Y, Liu K, Byrne S, Liu G, Wang X, Li Z, Ockleford CD. 2000. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation. Placenta 21:184-193.
9. Foca C, Moses EK, Quinn MA, Rice GE. 2000. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Gynecol Oncol 79:244-250.
10. Gleeson N, Gonsalves R, Bonnar J. 1992. The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol Oncol 47:58-61.
11. Hampton AL, Salamonsen LA. 1994. Expression of messenger ribonucleic acid encoding matrix metalloproteinases and their tissue inhibitors is related to menstruation. J Endocrinol 141:R1-R3.
12. Hampton AL, Butt AR, Riley SC, Salamonsen LA. 1995. Tissue inhibitors of metalloproteinases in endometrium of ovariectomized steroid-treated ewes during the estrous cycle and early pregnancy. Biol Reprod 53:302-311.
13. Higuchi T, Kanzaki H, Nakayama H, Fujimoto M, Hatayama H, Kojima K, Iwai M, Mori T, Fujita J. 1995. Induction of tissue inhibitor of metalloproteinase 3 gene expression during in vitro decidualization of human endometrial stromal cells. Endocrinology 136:4973-4981.
14. Hu ZY, Liu YX, Liu K, Byrne S, Ny T, Feng Q, Ockleford CD. 1999. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 194:183-195.
15. Hu J, Zhang X, Nothnick WB, Spencer TE. 2004. Characterization of matrix metalloproteases and their tissue inhibitors in neonatal mouse uterus. Biol Reprod 71:1598-1604.
16. Hulboy DL, Rudolph LA, Matrisian LM. 1997. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3:27-45.
17. Inagi R, Miyata T, Suzuki D, Toyoda M, Wada T, Ueda Y, Izuhara Y, Sakai H, Nangaku M, Kurokawa K. 2001. Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its upregulation in IgA nephropathy. Biochem Biophys Res Commun 286:1098-1106.
18. Jones PL, Schmidhauser C, Bissell MJ. 1993. Regulation of gene expression and cell function by extracellular matrix. Crit Rev Eukaryotic Gene Expr 3:137-154.
19. Kawano T, Morimoto K, Uemura Y. 1970. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 67:333-342.
20. Lessey BA, Castelbaum AJ, Sawin SW, Buck CA, Schinnar R, Bilker W, Strom BL. 1994. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab 79:643-649.
21. Lian X, Yang T. 2004. Plasminogen activator inhibitor 2: Expression and role in differentiation of epidermal keratinocyte. Biol Cell 96:109-116.
22. Liu YX, Hu ZY, Liu K, Byrne S, Zou RJ, Ny T, d'Lacey C, Ockleford CD. 1998. Localization and distribution of tissue type and urokinase type plasminogen activators and their inhibitors Type 1 and 2 in human and rhesus monkey fetal membranes. Placenta 19:171-180.
23. Miyata T, Nangaku M, Suzuki D, Inagi R, Uragami K, Sakai H, Okubo K, Kurokawa K. 1998. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest 102:828-836.
24. Miyata T, Inagi R, Nangaku M, Imasawa T, Sato M, Izuhara Y, Suzuki D, Atsusi Y, Onogi H, Kimura M, Sugiyama S, Kurokawa K. 2002. Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J Clin Invest 109:585-593.
25. Nangaku M, Miyata T, Suzuki D, Umezono T, Hashimoto T, Wada T, Yagi M, Nagano N, Inagi R, Kurokawa K. 2001. Cloning of rodent megsin revealed its up-regulation in mesangioproliferative nephritis. Kidney Int 60:641-652.
26. Nothnick WB. 2000. Disruption of the tissue inhibitor of metalloproteinase-1 gene results in altered reproductive cyclicity, and uterine morphology in reproductive-age female mice. Biol Reprod 63:905-912.
27. Nothnick WB. 2001a. Disruption of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene in reproductive-age female mice is associated with estrous cycle stage-specific increases in stromelysin mRNA expression and activity. Biol Reprod 65:1780-1788.
28. Nothnick WB. 2001b. Reduction of reproductive lifespan in tissue inhibitor of metalloproteinase-1 (TIMP-1) deficient female mice. Reproduction 122:923-927.
29. Nothnick WB, Soloway PD, Curry TE, Jr. 1997. Assessment of the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) during the peri-ovulatory period in female mice lacking a functional TIMP-1 gene. Biol Reprod 56:1181-1188.
30. Nothnick WB, Zhang X, Zhou H-E. 2004. Steroidal regulation of uterine edema and TIMP-3 mRNA expression is altered in TIMP-1 deficient mice. Biol Reprod 70:500-508.
31. Ra H-J, Parks WC. 2007. Control of matrix metalloproteinase catalytic activity. Matrix Biol 26:587-596.
32. Rodgers WH, Osteen KG, Matrisian LM, Navre M, Gorstein F. 1993. Expression and localization of matrilysin, a matrix metalloproteinase, in the human endometrium. Am J Obstet Gynecol 168:253-260.
33. Rodgers WH, Matrisian LM, Giudice LC, Dsupin B, Cannon P, Svitek C, Gorstein F, Osteen KG. 1994. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 94:946-953.
34. Rudolph-Owen LA, Hulboy DL, Wilson CE, Mudgett J, Matrisian LM. 1997. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 138:4902-4911.
35. Rudolph-Owen LA, Slayden OD, Matrisian LM, Brenner RM. 1998. Matrix metalloproteinase expression in Macaca mulatta endometrium: Evidence for zone-specific regulatory tissue gradients. Biol Reprod 59:1349-1359.
36. Smith R, Xue A, Gill A, Scarlett C, Saxby A, Clarkson A, Hugh T. 2007. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 31:493-502.
37. Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissel MJ, Werb Z. 1994. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 125:681-693.
38. Vincenti MP, Barinckefhoff CE. 2007. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: Can MMPs be good for you? J Cell Physiol 213:355-364.
39. Wolf K, Sandner P, Kurtz A, Moll W. 1996. Messenger ribonucleic acid levels of collagenase (MMP-13) and matrilysin (MMP-7) in virgin, pregnant and postpartum uterus and cervix of rat. Endocrinology 137:5429-5434.
40. Yu H, Maurer F, Medcalf RL. 2002. Plasminogen activator inhibitor type 2: A regulator of monocytes proliferation and differentiation. Blood 99:2810-2818.
41. Zhang J, Salamonsen LA. 1997. Tissue inhibitor of metalloproteinases (TIMP)-1, -2, and -3 in human endometrium during the menstrual cycle. Mol Hum Reprod 3:735-741.